Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Share-based Compensation (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Share-based Compensation data on record, last reported at $7.3 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 158.04% year-over-year to $7.3 million; the TTM value through Sep 2025 reached $24.3 million, up 275.51%, while the annual FY2024 figure was $10.8 million, 209.61% up from the prior year.
  • Share-based Compensation reached $7.3 million in Q3 2025 per ZBIO's latest filing, up from $6.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.3 million in Q3 2025 and bottomed at $947000.0 in Q1 2024.
  • Average Share-based Compensation over 3 years is $3.8 million, with a median of $4.1 million recorded in 2024.
  • The widest YoY moves for Share-based Compensation: up 468.74% in 2025, down 158.04% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $1.1 million in 2023, then skyrocketed by 384.14% to $5.5 million in 2024, then skyrocketed by 33.5% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $7.3 million in Q3 2025, $6.0 million in Q2 2025, and $5.4 million in Q1 2025.